09.11.2023 • News

Elixir and K+S to Produce and Distribute Fertilizer MAP

Serbian agrochemicals producer Elixir Group and German minerals producer K+S have signed a cooperation agreement for the production and distribution of crystalline water-soluble fertilizer mono-ammonium phosphate (MAP).

Under the terms of the partnership, Elixir will construct a new factory for the production of MAP with a nameplate capacity of 50,000 t/a at its site in Prahovo, Serbia. This location was chosen because the supply of phosphoric acid, which is the key raw material for this product, is ensured there. The amount of the investment was estimated at €35 million. Partner K+S will be responsible for the global distribution of the product with a focus on the European, Eastern European and Indian markets.

According to Elixir, engineering work has begun, while the construction is expected to start in spring 2024. The start of production and availability of the first quantities of crystalline MAP from the new factory in Prahovo is expected in early 2026.

MAP is a highly concentrated free-flowing water-soluble fertilizer containing 12% nitrogen and 61% phosphorus, in the form of crystals. It is used in modern fruit and vegetable production and applied through drip irrigation systems. In this way, plants efficiently absorb nutrients, which results in higher yields and better quality of agricultural products in every growth stage. Further, crystalline MAP is increasingly used and in demand as a raw material in other industrial branches, Elixir said.

© K+S
© K+S

Company

Logo:

Elixir Group DOO

Bulevar Oslobođenja 79
21000 Novi Sad
Serbia

Company contact







Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.